March 9, 2020 / 1:45 PM / 19 days ago

BRIEF-Myovant Sciences Submits Marketing Authorization Application To The European Medicines Agency For Relugolix Combination Tablet

March 9 (Reuters) - Myovant Sciences Ltd:

* MYOVANT SCIENCES SUBMITS MARKETING AUTHORIZATION APPLICATION TO THE EUROPEAN MEDICINES AGENCY FOR RELUGOLIX COMBINATION TABLET FOR THE TREATMENT OF WOMEN WITH UTERINE FIBROIDS

* MYOVANT SCIENCES LTD - NDA TO FDA PLANNED FOR SUBMISSION IN APRIL 2020 FOR RELUGOLIX COMBINATION TABLET

* MYOVANT SCIENCES LTD - IF APPROVED, RELUGOLIX COMBINATION TABLET WOULD OFFER A ONE PILL, ONCE-A-DAY TREATMENT OPTION FOR WOMEN WITH UTERINE FIBROIDS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below